Best Practices for Monitoring and Management of OT Teprotumumab-Associated Hyperglycemia in Thyroid Eye Disease

Sponsored Supplement: Best Practices for Monitoring and Management of OT Teprotumumab-Associated Hyperglycemia in Thyroid Eye Disease

Teprotumumab is the first and only FDA-approved medication for thyroid eye disease (TED). Teprotumumab has demonstrated efficacy in improving proptosis, diplopia, measures of quality of life, and inflammation in patients with TED, but is also associated with treatment-emergent hyperglycemia in approximately 10% of treated patients, most commonly those with baseline diabetes or prediabetes. This sponsored supplement reviews the evidence to date on teprotumumab-associated hyperglycemia, risk factors for experiencing hyperglycemia, and best practices for assessing, monitoring, and managing glycemic control in patients being considered for teprotumumab therapy.